EGFR and non-small cell lung carcinoma: Nevertheless, subsequent randomized controlled trials (RCTs) yielded conflicting results with respect to whether adjuvant EGFR-TKIs treatment compared to placebo or adjuvant chemotherapy could improve the prognosis of patients with operable NSCLC [17–24].